{
    "organizations": [],
    "uuid": "72b528ed23de5bee27fa21b1ce214d17c9267981",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-insmed-announces-fda-acceptance-fo/brief-insmed-announces-fda-acceptance-for-filing-of-nda-for-lung-disease-treatment-idUSASC0A2L6",
    "ord_in_thread": 0,
    "title": "BRIEF-Insmed Announces FDA Acceptance For Filing Of NDA For Lung Disease Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Insmed Inc:\n* INSMED ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC\n* INSMED INC - PDUFA ACTION DATE SET FOR SEPTEMBER 28, 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-16T20:16:00.000+03:00",
    "crawled": "2018-05-17T14:24:23.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "insmed",
        "inc",
        "insmed",
        "announces",
        "fda",
        "acceptance",
        "filing",
        "new",
        "drug",
        "application",
        "ali",
        "ntm",
        "lung",
        "disease",
        "caused",
        "mac",
        "insmed",
        "inc",
        "pdufa",
        "action",
        "date",
        "set",
        "september",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}